Schroeder, Sophia E.
Wilkinson, A. L.
O’Keefe, D.
Bourne, A.
Doyle, J. S.
Hellard, M.
Dietze, P.
Pedrana, A.
Article History
Received: 25 November 2022
Accepted: 14 January 2023
First Online: 23 January 2023
Declarations
:
: The SuperMIX study was approved by the Alfred Human Research Ethics Committee (Project: 599/21 SuperMIX 2021) and participants provided informed consent.
: Not applicable.
: MH and AP’s institution has received investigator-initiated research funding from Gilead Sciences, Abbvie and Merck. JD’s institution has received investigator-initiated research funding from Gilead and AbbVie and consultancies from Gilead and AbbVie. AP has received consultancies and travel honoraria from Gilead. DOK has received investigator-initiated research funding from Gilead Sciences. AB’s institution has received investigator-initiated research funding from ViiV. PD is funded by a National Health and Medical Research Council Senior Research Fellowship and has received investigator-driven research funding from Gilead Sciences for work on hepatitis C unrelated to this study. PD has served as an unpaid member of an Advisory Board for an intranasal naloxone product. AW and SS have nothing to declare.